Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Evotec AG (EVO : NSDQ)

• Company Description    EVOTEC is a leader in the discovery and development of novel small molecule drugs. They have established a powerful platform that is applicable to targets across all therapeutic areas and has specific expertise in the area of Central Nervous System related diseases where it is building a pipeline of drug candidates for partnering. Through research collaborations and proprietary projects They are providing the highest quality research results to its partners in the pharmaceutical and biotechnology industries Number of Employees: 4,827

• Price / Volume Information    Yesterday's Closing Price: $3.08 Daily Weekly Monthly 20 Day Moving Average: 245,975 shares Shares Outstanding: 355.11 (millions) Market Capitalization: $1,093.73 (millions) Beta: 1.78 52 Week High: $4.80 52 Week Low: $2.84 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -4.64% -4.48% 12 Week -21.83% -23.09% Year To Date 0.00% 0.00%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL ESSENER BOGEN 7 - HAMBURG,2M 22419 DEU ph: 49-4056-0810 fax: 49-40-5608-1222 investorrelations@evotec.com http://www.evotec.com

• General Corporate Information    Officers Christian Wojczewski - Chief Executive Officer Craig Johnstone - Chief Operating Officer Laetitia Rouxel - Chief Financial Officer Volker Braun - Senior Vice President Anja Bosler - Principal Accounting Officer Peer Information Evotec AG (GSAC) Evotec AG (CASI) Evotec AG (ALCD.) Evotec AG (OMNN) Evotec AG (CGPI.) Evotec AG (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 30050E105 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: - Next Expected EPS Date: 11/05/25 Share - Related Items Shares Outstanding: 355.11 Most Recent Split Date: 10.00 (4.00:1) Beta: 1.78 Market Capitalization: $1,093.73 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $0.02 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.21 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 35.35% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/05/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.17 Price/Cash Flow: - Price / Sales: 1.31 EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -5.77% vs. Previous Quarter: -1.45% ROE 12/31/25 - - 09/30/25 - -18.20 06/30/25 - -16.94 ROA 12/31/25 - - 09/30/25 - -8.58 06/30/25 - -8.14 Current Ratio 12/31/25 - - 09/30/25 - 2.12 06/30/25 - 1.58 Quick Ratio 12/31/25 - - 09/30/25 - 2.03 06/30/25 - 1.49 Operating Margin 12/31/25 - - 09/30/25 - -21.24 06/30/25 - -20.14 Net Margin 12/31/25 - - 09/30/25 - -21.24 06/30/25 - -20.14 Pre-Tax Margin 12/31/25 - - 09/30/25 - -17.74 06/30/25 - -17.65 Book Value 12/31/25 - - 09/30/25 - 2.63 06/30/25 - 2.70 Inventory Turnover 12/31/25 - - 09/30/25 - 20.60 06/30/25 - 19.97 Debt-to-Equity 12/31/25 - - 09/30/25 - 0.48 06/30/25 - 0.42 Debt-to-Capital 12/31/25 - - 09/30/25 - 32.64 06/30/25 - 29.58

Powered by Zacks Investment Research ©